In 2022, Groupe Chevrillon invested in Astrea Pharma, a newly formed CDMO. Astrea Pharma’s first factory is located in Fontaine-lès-Dijon (France), with solid doses production capabilities.
In December 2024, Astrea Pharma acquired its second production site from Récipharm. This site, located in Monts (France), allows Astrea to diversify its client base and to produce liquid sterile products (prefilled vials).
